Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Tzschentke, Thomas

doi:10.1007/s00213-003-1626-4

Cited by 31 publications

(27 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that buprenorphine can induce psychomotor stimulation and reward (Rowlett et al, 1994;Smith et al, 2003;Sorge and Stewart, 2006;Sorge et al, 2005;Tzschentke, 2004). The results of the present study demonstrate that these actions of buprenorphine are mediated via the MOP.…”

Section: Discussionsupporting

confidence: 74%

The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference

et al. 2007

View full text Add to dashboard Cite

The analgesic effect of buprenorphine is mediated via the mu opioid receptor (MOP). In the present study, using mice lacking the MOP and their wild-type littermates, we determined the role of the MOP in buprenorphine-induced locomotor stimulation and conditioned place preference (CPP). Buprenorphine (3 mg/kg) increased motor activity in wild-type but not in MOP knockout mice, showing the motor stimulatory action of buprenorphine is mediated via the MOP. When the mice were given the same treatment once daily for 5 consecutive days and challenged with buprenorphine on day 11, the motor stimulatory action of buprenorphine was enhanced in wild-type but not in MOP knockout mice, showing sensitization developed to the motor stimulatory action of buprenorphine and this phenomenon was mediated via the MOP. Likewise, buprenorphine induced CPP in wildtype mice after four alternate-day saline/buprenorphine (3 mg/kg) injections paired with olfactory and visual cues. However, buprenorphine failed to induce CPP in MOP knockout mice. In contrast, amphetamine (1 mg/kg) induced a comparable CPP in wild-type and MOP knockout mice. Together, the present results suggest that the ability of buprenorphine to increase motor activity and induce locomotor sensitization and CPP is mediated via the MOP.

show abstract

Section: Discussionsupporting

confidence: 74%

The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that the presence of -opioid receptors is crucial for acquisition of naloxone-induced CPA because -opioid receptor knockout mice do not exhibit naloxone-induced CPA (Skoubis et al, 2001). In addition, it seems that partial agonist activity at -opioid receptors is sufficient to produce CPP because buprenorphine produces CPP (Tzschentke, 2004). Collectively, these findings suggest that the -opioid receptor is a critical component in mediating the oppositional CPP and CPA produced by opioid agonists and antagonists, respectively.…”

Section: Discussionmentioning

confidence: 81%

SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a Novel Mixed Nociceptin/Orphanin FQ/μ-Opioid Receptor Partial Agonist: Analgesic and Rewarding Properties in Mice

Khroyan¹,

Zaveri²,

Polgar³

et al. 2006

J Pharmacol Exp Ther

View full text Add to dashboard Cite

We identified a novel nociceptin/orphanin FQ (NOP)/-opioid receptor agonist, SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], with high binding affinity and partial agonist activity at both receptors. It was hypothesized that SR 16435 would produce antinociception and yet, unlike morphine, would have diminished rewarding properties and tolerance development. Antinociception was assessed in mice using the tail-flick assay, whereas behavioral and rewarding effects were assessed using the place conditioning (PC) paradigm. PC was established by pairing drug injections with a distinct compartment. Behavioral effects were measured after acute and repeated drug administration, and the test for PC was carried out 24 h after four drug-and vehicle-pairing sessions. SR 16435 produced an increase in tailflick latency, but SR 16435-induced antinociception was lower than that observed with morphine. Given that naloxone blocked SR 16435-induced antinociception, it is highly likely that this effect was mediated by -opioid receptors. Compared with morphine, chronic SR 16435 treatment resulted in reduced development of tolerance to its antinociceptive effects. SR 16435-induced conditioned place preference (CPP) was evident, an effect that was probably mediated via -opioid receptors, as it was reversed by coadministration of naloxone. NOP agonist activity was also present, given that SR 16435 decreased global activity, and this effect was partially reversed with the selective NOP antagonist, SR 16430 [1-(cyclooctylmethyl)-4-(3-(trifluoromethyl)phenyl)piperidin-4-ol]. Naloxone, however, also reversed the SR 16435-induced decrease in activity, indicating that both opioid and NOP receptors mediate this behavior. In summary, the mixed NOP/-opioid partial agonist SR 16435 exhibited both NOP and -opioid receptormediated behaviors.The NOP receptor [formerly known as the opioid receptorlike receptor (ORL1)] was discovered simultaneously by several groups on the basis of homology with the ␦-opioid receptor (Bunzow et al., 1994;Mollereau et al., 1994;Wang et al., 1994). This receptor has nucleotide and amino acid homology to the three opioid receptors; however, NOP receptors transfected into mammalian cells do not seem to bind opiates with high affinity. N/OFQ, the natural ligand for the NOP receptor, is a 17-amino acid neuropeptide (Meunier et al., 1995;Reinscheid et al., 1995). Although this peptide is in the opioid peptide family, N/OFQ has a different behavioral profile than that of typical opioid ligands. N/OFQ modulates nociception differentially, depending upon site of administration. N/OFQ This research was supported by National Institute on Drug Abuse Grant DA14026 (to N.T.Z.).Preliminary reports of these data were presented at the following annual meetings: Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F, and Toll L (2006) ,7,8, benzamide monohydrochloride; 1S,3,3a,4,5,3,decan-4-one; PC, place conditioning; CPP, conditioned place preference, CPA, conditioned place aversion; GTP␥S, gua...

show abstract

“…One plausible explanation could be that the low efficacy of SR14150 at MOPr may not be sufficient to produce reward. However, other MOPr partial agonists with similar efficacies at MOPr, such as pentazocine and buprenorphine, have been shown to produce CPP comparable with that produced by morphine (Suzuki et al, 1991;Tzschentke, 2004;Marquez et al, 2007). It is possible that CPP could be induced with higher doses of SR14150; however, significantly higher doses were impossible to test because of loss of muscle tone at higher doses of SR14150.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Antinociceptive and Antirewarding Profiles of Novel Bifunctional Nociceptin Receptor/μ-Opioid Receptor Ligands: Implications for Therapeutic Applications

Toll

Khroyan²,

Polgar³

et al. 2009

J Pharmacol Exp Ther

View full text Add to dashboard Cite

The nociceptin receptor (NOPr), a member of the opioid receptor family, is a target for the treatment of pain and drug abuse. Nociceptin/orphanin FQ (N/OFQ), the endogenous peptide for NOPr, not only modulates opioid antinociception, but also blocks the rewarding effects of several abused drugs, such as morphine, cocaine, and amphetamine. We hypothesized that NOPr agonists, with bifunctional activity at the -opioid receptor (MOPr), may function as nonaddicting analgesics or as drug abuse medications. Bifunctional small-molecule NOPr agonists possessing different selectivities and efficacies at MOPr were evaluated in an acute thermal antinociception assay, and for their ability to induce conditioned place preference (CPP) and their effect on morphineinduced CPP.

show abstract

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Cited by 31 publications

References 40 publications

The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference

The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference

SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a Novel Mixed Nociceptin/Orphanin FQ/μ-Opioid Receptor Partial Agonist: Analgesic and Rewarding Properties in Mice

Comparison of the Antinociceptive and Antirewarding Profiles of Novel Bifunctional Nociceptin Receptor/μ-Opioid Receptor Ligands: Implications for Therapeutic Applications

Contact Info

Product

Resources

About